recent data from Dendreon Corporati...

recent data from Dendreon Corporation's (Seattle, WA) Phase 3 clinical trial of Provenge confirms that a T-cell immune answer is consistent with the positive clinical answer seen in subjects with advanced, metastatic prostate cancer. The immune rejoinder data was collected from the double-blind, placebo-controlled trial, D9901 in men with androgen-independent prostate cancer. The terminates show that the close attention treatment induced a highly significant T-cell mediated immune